SCHOFIELD, Wis., Dec. 23, 2014 /PRNewswire/ -- PuraMed
BioScience®, Inc., (OTC Pink: PMBS), a researcher, developer, and
marketer of over-the-counter (OTC) medicinal and healthcare
products, announced it received the initial funding to begin final
production of MigraPure® H, a hemp-based, advanced headache relief
product, for planned distribution to 1,000 medical and recreational
marijuana dispensaries in Colorado, Washington
State, and California.
With the MigraPure H Advanced headache relief gel formulation
completed, PuraMed BioScience has turned its attention toward the
packaging for the initial launch. The Company announced it has
received its first round of funding, under its agreement with
FastFunds Financial Corporation (FFFC), which will be used to
finalize production, packaging and labeling of MigraPure H.
"The investment of FastFunds Financial puts us one step closer
to shipping MigraPure H," said Russell
Mitchell, CEO and Chairman of PuraMed BioScience. "With all
the recent legislative changes happening, the opportunity to break
into the cannabis market at this point is exciting. We hope to have
our first shipment of MigraPure H delivered to dispensaries by the
end of February.
"In addition to the dispensaries, we have several other
independent concerns interested in MigraPure H," said Mitchell.
"The year ahead looks promising."
PuraMed BioScience has finalized the package design and is
nearing completion of the labeling.
As of Dec. 05, 2014, the Company
had approximately 216 million common shares issued and
outstanding.
About MigraPure and MigraPure H
MigraPure Advanced
Migraine Relief is a sublingual feverfew and ginger gel that was
clinically tested under the name LipiGesic® M. The peppermint
flavor of this homeopathic, all-natural, over-the-counter migraine
headache pain reliever has been enhanced, but the clinically tested
active ingredients remain the same.
MigraPure H Advanced Headache Relief is PuraMed's most recent
all-natural, hemp-based headache reliever. The active ingredients
in MigraPure have been combined with a hemp-base to create a
powerful treatment for migraines and seizure-related headaches.
Early indications show the formulation may also be effective for
tension and cluster headaches and other epilepsy symptoms.
MigraPure H does not violate any Federal laws pertaining to the
cultivation, distribution or marketing of a controlled or banned
substance.
About PuraMed BioScience, Inc.
PuraMed BioScience
engages in the research, development, and marketing of
non-prescription medicinal and healthcare products.
PuraMed BioScience also specializes in the development of
sublingual homeopathic medications. This type of formulation
delivers active ingredients directly into the bloodstream for
faster relief and greater effectiveness with fewer side effects
than their chemical counterparts.
www.PuraMedBioScience.com
Forward-Looking Statements: This news release contains
forward-looking statements regarding PuraMed BioScience, Inc., and
its future business plans, which statements involve known and
unknown risks and uncertainties. Such risks and uncertainties may
cause actual results and future achievements of PuraMed BioScience
to be materially different than those implied by these
forward-looking statements. PuraMed BioScience has and undertakes
no obligation to provide public updates and revisions to these
forward-looking statements to reflect any changes in its
expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russ Mitchell
rmitchell@PuraMedBioScience.com
Phone: 715.359.6373
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/puramed-bioscience-nears-final-stages-needed-for-distribution-of-migrapure-h-300013461.html
SOURCE PuraMed BioScience, Inc.